{"pmid":32242878,"title":"Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis.","text":["Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis.","Novel coronavirus infection [coronavirus disease 2019 (COVID-19)] has spread to more than 203 countries of various regions including Africa, America, Europe, South East Asia and Western Pacific. The WHO had declared COVID-19 as the global public health emergency and subsequently as pandemic because of its worldwide spread. It is now one of the top-priority pathogens to be dealt with, because of high transmissibility, severe illness and associated mortality, wide geographical spread, lack of control measures with knowledge gaps in veterinary and human epidemiology, immunity and pathogenesis. The quick detection of cases and isolating them has become critical to contain it. To meet the increasing demand of the diagnostic services, it is necessary to enhance and expand laboratory capabilities since existing laboratories cannot meet the emerging demand. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a BSL-2 (Biosafety Level 2) agent and needs to be handled in biosafety cabinet using standard precautions. This review highlights minimum requirements for the diagnostic laboratories opting testing of material for the diagnosis of COVID-19 and associated biorisk to the individuals and to the community.","Indian J Med Res","Mourya, Devendra T","Sapkal, Gajanan","Yadav, Pragya D","Belani, Sujeet Kumar M","Shete, Anita","Gupta, Nivedita","32242878"],"abstract":["Novel coronavirus infection [coronavirus disease 2019 (COVID-19)] has spread to more than 203 countries of various regions including Africa, America, Europe, South East Asia and Western Pacific. The WHO had declared COVID-19 as the global public health emergency and subsequently as pandemic because of its worldwide spread. It is now one of the top-priority pathogens to be dealt with, because of high transmissibility, severe illness and associated mortality, wide geographical spread, lack of control measures with knowledge gaps in veterinary and human epidemiology, immunity and pathogenesis. The quick detection of cases and isolating them has become critical to contain it. To meet the increasing demand of the diagnostic services, it is necessary to enhance and expand laboratory capabilities since existing laboratories cannot meet the emerging demand. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a BSL-2 (Biosafety Level 2) agent and needs to be handled in biosafety cabinet using standard precautions. This review highlights minimum requirements for the diagnostic laboratories opting testing of material for the diagnosis of COVID-19 and associated biorisk to the individuals and to the community."],"journal":"Indian J Med Res","authors":["Mourya, Devendra T","Sapkal, Gajanan","Yadav, Pragya D","Belani, Sujeet Kumar M","Shete, Anita","Gupta, Nivedita"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32242878","week":"202014|Mar 30 - Apr 05","doi":"10.4103/ijmr.IJMR_763_20","keywords":["Biorisk - biosafety - diagnosis - infrastructure - laboratories - novel coronavirus"],"source":"PubMed","locations":["America"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1663079112828256257,"score":7.6048946,"similar":[{"pmid":32242830,"title":"Laboratory diagnostics within a modular hospital at the time of Coronavirus disease 2019 (COVID-19) in Wuhan.","text":["Laboratory diagnostics within a modular hospital at the time of Coronavirus disease 2019 (COVID-19) in Wuhan.","An outbreak of the so-called Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), has been spreading rapidly nationwide in China since December 2019. Wuhan, Hubei Province, is the hardest-hit region, with a rise in confirmed cases and its hospitals overwhelmed. On 2nd February, 2020, Wuhan began to build a modular hospital to treat patients caught with mild illness. The mobile modular hospital is mainly composed of medical modules, technical support modules, ward units, living support units and transportation capacity under field conditions, and there are complete equipment and specialized personnel to treat patients. Due to the severity and particularity of SARS-CoV-2, taking granted from lessons learnt from mobile modular hospitals, we use the existing large venues to construct a new fixed modular hospital. As patients need to be treated and tested, it is important to develop a clinical laboratory in the modular hospital and ensure biosafety. The construction of a clinical laboratory in the modular hospital is faced with problems such as time pressure, limited site selection, high level of biosafety, lack of experience and so forth. This paper mainly discusses how to construct the clinical laboratory in the modular hospital quickly and safely and put it into use to provide testing service for patients under various limited conditions.","Clin Chem Lab Med","Yusong, Liu","Duanliang, Peng","Jia, Yang","Dunyan, Chen","Hongbing, Jia","Siyuan, Yu","Huanhuan, Chen","Juan, Zhao","Lyurong, Liu","32242830"],"abstract":["An outbreak of the so-called Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), has been spreading rapidly nationwide in China since December 2019. Wuhan, Hubei Province, is the hardest-hit region, with a rise in confirmed cases and its hospitals overwhelmed. On 2nd February, 2020, Wuhan began to build a modular hospital to treat patients caught with mild illness. The mobile modular hospital is mainly composed of medical modules, technical support modules, ward units, living support units and transportation capacity under field conditions, and there are complete equipment and specialized personnel to treat patients. Due to the severity and particularity of SARS-CoV-2, taking granted from lessons learnt from mobile modular hospitals, we use the existing large venues to construct a new fixed modular hospital. As patients need to be treated and tested, it is important to develop a clinical laboratory in the modular hospital and ensure biosafety. The construction of a clinical laboratory in the modular hospital is faced with problems such as time pressure, limited site selection, high level of biosafety, lack of experience and so forth. This paper mainly discusses how to construct the clinical laboratory in the modular hospital quickly and safely and put it into use to provide testing service for patients under various limited conditions."],"journal":"Clin Chem Lab Med","authors":["Yusong, Liu","Duanliang, Peng","Jia, Yang","Dunyan, Chen","Hongbing, Jia","Siyuan, Yu","Huanhuan, Chen","Juan, Zhao","Lyurong, Liu"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32242830","week":"202014|Mar 30 - Apr 05","doi":"10.1515/cclm-2020-0332","keywords":["COVID-19","biological safety","handheld system","modular hospital"],"source":"PubMed","locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1663079112830353408,"score":202.49586},{"pmid":32237288,"title":"Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea.","text":["Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea.","The outbreak of coronavirus disease 2019 (COVID-19), which began in December 2019, is still ongoing in Korea, with >9,000 confirmed cases as of March 25, 2020. COVID-19 is a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection, and real-time reverse transcription-PCR is currently the most reliable diagnostic method for COVID-19 around the world. Korean Society for Laboratory Medicine and the Korea Centers for Disease Prevention and Control propose guidelines for diagnosing COVID-19 in clinical laboratories in Korea. These guidelines are based on other related domestic and international guidelines, as well as expert opinions and include the selection of test subjects, selection of specimens, diagnostic methods, interpretation of test results, and biosafety.","Ann Lab Med","Hong, Ki Ho","Lee, Sang Won","Kim, Taek Soo","Huh, Hee Jae","Lee, Jaehyeon","Kim, So Yeon","Park, Jae Sun","Kim, Gab Jeong","Sung, Heungsup","Roh, Kyoung Ho","Kim, Jae Seok","Kim, Hyun Soo","Lee, Seung Tae","Seong, Moon Woo","Ryoo, Namhee","Lee, Hyukmin","Kwon, Kye Chul","Yoo, Cheon Kwon","32237288"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19), which began in December 2019, is still ongoing in Korea, with >9,000 confirmed cases as of March 25, 2020. COVID-19 is a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection, and real-time reverse transcription-PCR is currently the most reliable diagnostic method for COVID-19 around the world. Korean Society for Laboratory Medicine and the Korea Centers for Disease Prevention and Control propose guidelines for diagnosing COVID-19 in clinical laboratories in Korea. These guidelines are based on other related domestic and international guidelines, as well as expert opinions and include the selection of test subjects, selection of specimens, diagnostic methods, interpretation of test results, and biosafety."],"journal":"Ann Lab Med","authors":["Hong, Ki Ho","Lee, Sang Won","Kim, Taek Soo","Huh, Hee Jae","Lee, Jaehyeon","Kim, So Yeon","Park, Jae Sun","Kim, Gab Jeong","Sung, Heungsup","Roh, Kyoung Ho","Kim, Jae Seok","Kim, Hyun Soo","Lee, Seung Tae","Seong, Moon Woo","Ryoo, Namhee","Lee, Hyukmin","Kwon, Kye Chul","Yoo, Cheon Kwon"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32237288","week":"202014|Mar 30 - Apr 05","keywords":["COVID-19","Guidelines","Korea","Laboratory diagnosis","Outbreak"],"source":"PubMed","locations":["South Korea"],"countries":["Korea, Republic of"],"countries_codes":["KOR|Korea, Republic of"],"topics":["Diagnosis"],"weight":1,"_version_":1662996001629143040,"score":193.67305},{"pmid":32232423,"title":"Safety Recommendations for Evaluation and Surgery of the Head and Neck During the COVID-19 Pandemic.","text":["Safety Recommendations for Evaluation and Surgery of the Head and Neck During the COVID-19 Pandemic.","Importance: The rapidly expanding novel coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has challenged the medical community to an unprecedented degree. Physicians and health care workers are at added risk of exposure and infection during the course of patient care. Because of the rapid spread of this disease through respiratory droplets, health care workers who come in close contact with the upper aerodigestive tract during diagnostic and therapeutic procedures, such as otolaryngologists-head and neck surgeons, are particularly at risk. A set of safety recommendations was created based on a review of the literature and communications with physicians with firsthand knowledge of safety procedures during the COVID-19 pandemic. Observations: A high number of health care workers were infected during the first phase of the pandemic in the city of Wuhan, China. Subsequently, by adopting strict safety precautions, other regions were able to achieve high levels of safety for health care workers without jeopardizing the care of patients. The most common procedures related to the examination and treatment of upper aerodigestive tract diseases were reviewed. Each category was reviewed based on the potential risk imposed to health care workers. Specific recommendations were made based on the literature, when available, or consensus best practices. Specific safety recommendations were made for performing tracheostomy in patients with COVID-19. Conclusions and Relevance: Preserving a highly skilled health care workforce is a top priority for any community and health care system. Based on the experience of health care systems in Asia and Europe, by following strict safety guidelines, the risk of exposure and infection of health care workers could be greatly reduced while providing high levels of care. The provided recommendations, which may evolve over time, could be used as broad guidance for all health care workers who are involved in the care of patients with COVID-19.","JAMA Otolaryngol Head Neck Surg","Givi, Babak","Schiff, Bradley A","Chinn, Steven B","Clayburgh, Daniel","Iyer, N Gopalakrishna","Jalisi, Scharukh","Moore, Michael G","Nathan, Cherie-Ann","Orloff, Lisa A","O'Neill, James P","Parker, Noah","Zender, Chad","Morris, Luc G T","Davies, Louise","32232423"],"abstract":["Importance: The rapidly expanding novel coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has challenged the medical community to an unprecedented degree. Physicians and health care workers are at added risk of exposure and infection during the course of patient care. Because of the rapid spread of this disease through respiratory droplets, health care workers who come in close contact with the upper aerodigestive tract during diagnostic and therapeutic procedures, such as otolaryngologists-head and neck surgeons, are particularly at risk. A set of safety recommendations was created based on a review of the literature and communications with physicians with firsthand knowledge of safety procedures during the COVID-19 pandemic. Observations: A high number of health care workers were infected during the first phase of the pandemic in the city of Wuhan, China. Subsequently, by adopting strict safety precautions, other regions were able to achieve high levels of safety for health care workers without jeopardizing the care of patients. The most common procedures related to the examination and treatment of upper aerodigestive tract diseases were reviewed. Each category was reviewed based on the potential risk imposed to health care workers. Specific recommendations were made based on the literature, when available, or consensus best practices. Specific safety recommendations were made for performing tracheostomy in patients with COVID-19. Conclusions and Relevance: Preserving a highly skilled health care workforce is a top priority for any community and health care system. Based on the experience of health care systems in Asia and Europe, by following strict safety guidelines, the risk of exposure and infection of health care workers could be greatly reduced while providing high levels of care. The provided recommendations, which may evolve over time, could be used as broad guidance for all health care workers who are involved in the care of patients with COVID-19."],"journal":"JAMA Otolaryngol Head Neck Surg","authors":["Givi, Babak","Schiff, Bradley A","Chinn, Steven B","Clayburgh, Daniel","Iyer, N Gopalakrishna","Jalisi, Scharukh","Moore, Michael G","Nathan, Cherie-Ann","Orloff, Lisa A","O'Neill, James P","Parker, Noah","Zender, Chad","Morris, Luc G T","Davies, Louise"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232423","week":"202014|Mar 30 - Apr 05","doi":"10.1001/jamaoto.2020.0780","source":"PubMed","locations":["Physicians","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1662899337756147714,"score":193.11504},{"pmid":32156101,"title":"Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19).","text":["Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19).","The severe acute respiratory coronavirus 2 (SARS-CoV-2), which emerged in December 2019 in Wuhan, China, has spread rapidly to over a dozen countries. Especially, the spike of case numbers in South Korea sparks pandemic worries. This virus is reported to spread mainly through personto- person contact via respiratory droplets generated by coughing and sneezing, or possibly through surface contaminated by people coughing or sneezing on them. More critically, there have been reports about the possibility of this virus to transmit even before a virus-carrying person to show symptoms. Therefore, a low-cost, easy-access protocol for early detection of this virus is desperately needed. Here, we have established a real-time reverse-transcription PCR (rtPCR)-based assay protocol composed of easy specimen self-collection from a subject via pharyngeal swab, Trizolbased RNA purification, and SYBR Green-based rtPCR. This protocol shows an accuracy and sensitivity limit of 1-10 virus particles as we tested with a known lentivirus. The cost for each sample is estimated to be less than 15 US dollars. Overall time it takes for an entire protocol is estimated to be less than 4 hours. We propose a cost-effective, quick-and-easy method for early detection of SARS-CoV-2 at any conventional Biosafety Level II laboratories that are equipped with a rtPCR machine. Our newly developed protocol should be helpful for a first-hand screening of the asymptomatic virus-carriers for further prevention of transmission and early intervention and treatment for the rapidly propagating virus.","Exp Neurobiol","Won, Joungha","Lee, Solji","Park, Myungsun","Kim, Tai Young","Park, Mingu Gordon","Choi, Byung Yoon","Kim, Dongwan","Chang, Hyeshik","Kim, V Narry","Lee, C Justin","32156101"],"abstract":["The severe acute respiratory coronavirus 2 (SARS-CoV-2), which emerged in December 2019 in Wuhan, China, has spread rapidly to over a dozen countries. Especially, the spike of case numbers in South Korea sparks pandemic worries. This virus is reported to spread mainly through personto- person contact via respiratory droplets generated by coughing and sneezing, or possibly through surface contaminated by people coughing or sneezing on them. More critically, there have been reports about the possibility of this virus to transmit even before a virus-carrying person to show symptoms. Therefore, a low-cost, easy-access protocol for early detection of this virus is desperately needed. Here, we have established a real-time reverse-transcription PCR (rtPCR)-based assay protocol composed of easy specimen self-collection from a subject via pharyngeal swab, Trizolbased RNA purification, and SYBR Green-based rtPCR. This protocol shows an accuracy and sensitivity limit of 1-10 virus particles as we tested with a known lentivirus. The cost for each sample is estimated to be less than 15 US dollars. Overall time it takes for an entire protocol is estimated to be less than 4 hours. We propose a cost-effective, quick-and-easy method for early detection of SARS-CoV-2 at any conventional Biosafety Level II laboratories that are equipped with a rtPCR machine. Our newly developed protocol should be helpful for a first-hand screening of the asymptomatic virus-carriers for further prevention of transmission and early intervention and treatment for the rapidly propagating virus."],"journal":"Exp Neurobiol","authors":["Won, Joungha","Lee, Solji","Park, Myungsun","Kim, Tai Young","Park, Mingu Gordon","Choi, Byung Yoon","Kim, Dongwan","Chang, Hyeshik","Kim, V Narry","Lee, C Justin"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32156101","week":"202011|Mar 09 - Mar 15","doi":"10.5607/en20009","keywords":["COVID-19","Communicable diseases","Coronavirus","Diagnostic techniques and procedures","Emerging","Infectious disease","SARS virus"],"source":"PubMed","locations":["China","South Korea","Wuhan"],"countries":["China","Korea, Republic of"],"countries_codes":["CHN|China","KOR|Korea, Republic of"],"topics":["Diagnosis"],"weight":1,"_version_":1662334543830450177,"score":190.2234},{"pmid":32145185,"title":"Middle East respiratory syndrome.","text":["Middle East respiratory syndrome.","The Middle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen that was first identified in humans in Saudi Arabia and Jordan in 2012. Intermittent sporadic cases, community clusters, and nosocomial outbreaks of MERS-CoV continue to occur. Between April 2012 and December 2019, 2499 laboratory-confirmed cases of MERS-CoV infection, including 858 deaths (34.3% mortality) were reported from 27 countries to WHO, the majority of which were reported by Saudi Arabia (2106 cases, 780 deaths). Large outbreaks of human-to-human transmission have occurred, the largest in Riyadh and Jeddah in 2014 and in South Korea in 2015. MERS-CoV remains a high-threat pathogen identified by WHO as a priority pathogen because it causes severe disease that has a high mortality rate, epidemic potential, and no medical countermeasures. This Seminar provides an update on the current knowledge and perspectives on MERS epidemiology, virology, mode of transmission, pathogenesis, diagnosis, clinical features, management, infection control, development of new therapeutics and vaccines, and highlights unanswered questions and priorities for research, improved management, and prevention.","Lancet","Memish, Ziad A","Perlman, Stanley","Van Kerkhove, Maria D","Zumla, Alimuddin","32145185"],"abstract":["The Middle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen that was first identified in humans in Saudi Arabia and Jordan in 2012. Intermittent sporadic cases, community clusters, and nosocomial outbreaks of MERS-CoV continue to occur. Between April 2012 and December 2019, 2499 laboratory-confirmed cases of MERS-CoV infection, including 858 deaths (34.3% mortality) were reported from 27 countries to WHO, the majority of which were reported by Saudi Arabia (2106 cases, 780 deaths). Large outbreaks of human-to-human transmission have occurred, the largest in Riyadh and Jeddah in 2014 and in South Korea in 2015. MERS-CoV remains a high-threat pathogen identified by WHO as a priority pathogen because it causes severe disease that has a high mortality rate, epidemic potential, and no medical countermeasures. This Seminar provides an update on the current knowledge and perspectives on MERS epidemiology, virology, mode of transmission, pathogenesis, diagnosis, clinical features, management, infection control, development of new therapeutics and vaccines, and highlights unanswered questions and priorities for research, improved management, and prevention."],"journal":"Lancet","authors":["Memish, Ziad A","Perlman, Stanley","Van Kerkhove, Maria D","Zumla, Alimuddin"],"date":"2020-03-08T11:00:00Z","year":2020,"_id":"32145185","week":"202010|Mar 02 - Mar 08","doi":"10.1016/S0140-6736(19)33221-0","source":"PubMed","locations":["Saudi Arabia","Riyadh","Jeddah","South Korea","Jordan"],"countries":["Saudi Arabia","Korea, Republic of","Jordan"],"countries_codes":["SAU|Saudi Arabia","KOR|Korea, Republic of","JOR|Jordan"],"topics":["Transmission","Treatment","Diagnosis","Prevention","Mechanism"],"weight":1,"_version_":1663095626034839552,"score":182.33582}]}